№ lp_1_2_57216
File format: docx
Character count: 9538
File size: 57 KB
The document is an agreement outlining the terms and conditions for telework arrangements between employees and their managers at the University of Washington.
Year:
2023
Region / City:
Washington
Theme:
Telework, Employment
Document Type:
Agreement
Organization / Institution:
University of Washington
Author:
Not specified
Target Audience:
Employees, Managers
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Context:
A document explaining the policies, benefits, and considerations related to teleworking, outlining responsibilities for both employees and employers.
Note:
Year
Subject:
Telework arrangement
Document Type:
Agreement
Institution / Organization:
University
Contextual description:
Agreement outlining the terms and conditions for hybrid or occasional telework for employees, including equipment provision and expectations.
Year:
2025
Region / City:
California
Topic:
Telework, Disability Accommodation, Employee Rights
Document Type:
FAQ
Organization / Institution:
ACSED
Author:
Not specified
Target Audience:
State employees in California
Effective Period:
Starting July 1, 2025
Approval Date:
March 3, 2025
Amendment Date:
March 13, 2025
Organization:
Insert Agency Name
Document Type:
Policy Statement
Subject:
Teleworking and Remote Work Assignments
Scope:
All agency offices, departments, divisions, and employees
Authority:
Agency Head or Appointing Authority
Implementation Responsibility:
Department Directors or Designees
Coverage:
Employees Approved for Telework
Key Sections:
Policy Statement; Purpose; Scope; Policy Details; Program Guidelines; Work Hours; Worksite; Equipment and Supplies
Cost Provisions:
Telework Assignments Intended to Be Cost Neutral
Liability Provisions:
Agency Not Liable for Personal Property Damage at Alternate Worksite
Year:
2020
Region / City:
Maryland
Theme:
Telework, COVID-19
Document Type:
Guidelines
Organization:
Notre Dame of Maryland University
Author:
Not specified
Target Audience:
NDMU employees
Period of validity:
During COVID-19 pandemic
Approval Date:
Not specified
Date of Changes:
Not specified
Context:
Temporary guidelines outlining the terms and conditions for teleworking at Notre Dame of Maryland University during the COVID-19 pandemic.
Year:
2021
Region / city:
Not specified
Topic:
Employee retention, flexible work arrangements, telework
Document type:
Research paper
Institution:
Not specified
Author:
Not specified
Target audience:
Employers, HR professionals, researchers
Period of validity:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2023
Region / City:
University-wide
Topic:
Telework Guidelines and Procedures
Document Type:
Internal Memo
Organization:
University
Author:
Human Resources Department
Target Audience:
Supervisors and Employees
Approval Date:
N/A
Modification Date:
N/A
Note:
Year
Year:
2020
Region / City:
Wake County, North Carolina, USA
Topic:
Cybersecurity and Remote Work
Document Type:
Guidelines / Information Notice
Organization:
Wake County Information Services
Author:
Wake County Information Services Security Team
Target Audience:
Wake County employees
Effective Period:
During the coronavirus outbreak
Approval Date:
Not specified
Last Updated:
Not specified
Distribution Method:
Internal county network, email notifications
Year:
2025
Region / City:
Australia
Topic:
Pharmaceutical submission for drug listing
Document Type:
Pharmaceutical submission
Organization:
Janssen-Cilag Pty Ltd
Author:
Not specified
Target Audience:
Healthcare professionals, regulatory authorities
Validity Period:
Not specified
Approval Date:
Not specified
Date of Changes:
March 2025
Note:
Context
Year:
2025
Region / City:
[insert local health board name]
Topic:
Community Pharmacy, Common Ailments Service, Docusate Sodium
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
Welsh Medicines Advice Service
Author:
Dianne Burnett
Target Audience:
Pharmacists working within the Common Ailments Service of the Clinical Community Pharmacy Service
Period of Validity:
01 November 2025 - 31 October 2028
Approval Date:
29 August 2025
Review Date:
31 July 2028
Expiration Date:
31 October 2028
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2025
Region / city:
Australia
Subject:
Vocational Education and Training, Health Industry Training
Document type:
Implementation Guide
Organization:
HumanAbility
Author:
HumanAbility, Commonwealth Government through the Department of Employment and Workplace Relations
Target audience:
Registered Training Organisations (RTOs), trainers, assessors, and stakeholders in the VET sector
Period of validity:
September 2025
Approval date:
September 2025
Modification date:
Not specified
Year:
2024
Region / City:
Australia
Topic:
Immunization, Respiratory Syncytial Virus (RSV), Vaccines
Document Type:
Submission
Organization:
SANOFI-AVENTIS AUSTRALIA PTY LTD
Author:
Not specified
Target Audience:
Healthcare professionals, policy makers, immunization program administrators
Period of validity:
From 2024
Approval Date:
24 November 2023
Date of Changes:
17 January 2025
Date of Submission:
7 March 2024
Note:
Contextual Description
Year:
2024
Region / City:
Victoria
Theme:
Agriculture, Horticulture, Conservation, Land Management
Document Type:
Official Guide
Institution:
Department of Jobs, Skills, Industry and Regions (DJSIR)
Author:
Department of Jobs, Skills, Industry and Regions
Target Audience:
Registered Training Organisations (RTOs)
Period of Validity:
From June 2024
Approval Date:
17 June 2024
Changes Date:
N/A
Year:
2022
Region / City:
Australia
Topic:
Medical treatment approval and submission for pembrolizumab and lenvatinib
Document type:
Submission for drug listing
Organization / Institution:
Pharmaceutical Benefits Advisory Committee (PBAC), Therapeutic Goods Administration (TGA)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Medical professionals, health regulators
Period of validity:
2022 onward
Approval date:
August 10, 2021
Amendment date:
Not specified
Year:
2023
Region / city:
Australia
Theme:
Oncology, Chronic Lymphocytic Leukaemia
Document Type:
Resubmission Report
Organization:
AstraZeneca Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, healthcare policymakers
Period of validity:
Not specified
Approval Date:
November 2019
Date of Changes:
December 2022
Year:
2018
Region / City:
Not specified
Topic:
Performance Qualification for Sequencing System
Document Type:
Protocol
Organization / Institution:
Illumina, Inc.
Author:
Illumina, Inc.
Target Audience:
Illumina certified personnel
Period of Validity:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2020
Region / City:
Australia
Topic:
Pharmaceutical Benefits Scheme (PBS) listing
Document Type:
Committee Submission
Agency:
PBAC (Pharmaceutical Benefits Advisory Committee)
Author:
Committee Secretariat
Target Audience:
Healthcare professionals, PBAC members
Period of Effect:
From May 13, 2020
Approval Date:
May 13, 2020
Modification Date:
Not specified
Year:
2022
Region / City:
Electronic Meeting
Topic:
NR-U bands n46 and n96 – 100 MHz channel BW
Document type:
Meeting Document
Author:
Qualcomm
Target Audience:
RAN4 WG
Period of validity:
February 21 – March 3, 2022
Approval Date:
Not specified
Date of modifications:
Not specified
Description:
A document detailing the discussion and proposals regarding the inclusion of 100 MHz channel bandwidth in NR-U bands n46 and n96, focusing on the coexistence with other technologies and possible configurations.